Meet our new CEO, Tord Labuda!
Date: 2024-10-11
In a recent interview with BioStock - Connecting Innovation and Capital, Tord shares insights into his extensive background in the pharmaceutical industry, his vision for Alzinova AB, and the exciting path ahead.
With the phase Ib clinical trial of our Alzheimer’s vaccine ALZ-101 on track for completion in early 2025, and preparations for phase II, Tord discusses the opportunities that lie ahead for both Alzinova and the industry.
Read the interview!